207results about "Silicon compound active ingredients" patented technology

A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;

Compounds and compositions capable of modulating immune responses in patients, as well as implantable elements containing them, are provided. [Solution] For example, 4-((1-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)thiomorpholine 1,1-dioxide, as well as pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives and compositions thereof, and implantable elements (e.g., devices and materials) containing these are provided.

The present disclosure provides compounds, compositions, and methods for treating or preventing neurological disorders in a patient. The disclosed methods include administration to a subject suffering from a neurological disorder of a compound disclosed herein.

The invention relates to a high frequency magnetic induction device (100). The device (100) comprises magnetic nanosuspension (101) and an AMF generator (103). The AMF generator (103) further comprises copper induction coil (104), work head (105), flexible connector (106), power supply (107), chiller (108), display and control unit (109), fiberoptic thermometer sensors (110a &110b), auto-manual toggle switch (111), USB port (112a &112b) and bed support (113). Tumor site enclosed by the magnetic nanosuspension (101) comprising iron oxide magnetic nanoparticles (102) generates heat when exposed to AMF generated by the AMF generator (103). The heat generated does not cause any harm to the healthy tissues. The AMF generator (103) has precise control over thermal doses generated. The high frequency induction device (100) is safe, effective, non-invasive with mild side-effects.

Provided herein are methods of treatment, including methods of treating subjects having or at risk of having or having a viral infection, and specifically a SARS-CoV-2 viral infection. The methods provided include the administration of 4-methylumbelliferone (4-MU), palmitoylethanolamide (PEA), reservatrol, fisetin, H2, nebulized hyaluronidase or combinations thereof. Also provided herein are a respiratory assistance device, methods of generating a customized respiratory assistance device, methods of treating a coronavirus infection, and methods of inhibiting a coronavirus infectivity, virulence and / or spread.

The purpose of the present invention is to provide a novel blood-brain barrier permeability regulator.　The present invention pertains to a blood-brain barrier permeability regulator containing a compound represented by formula (I) (Symbols in the formula (I) are as defined in the present specification.) or an isomer thereof, or a salt thereof. The present invention also pertains to a medicine for preventing and / or treating various brain diseases, severe infections, or sepsis by using the compound or an isomer thereof, or a salt thereof alone or in combination with a drug for preventing and / or treating a brain disease.

Provided herein are compositions comprising a silicate, inositol, and optionally an amino acid, which have improved solubility and / or are crystalline. Also provided are methods of making the disclosed compositions, as well as methods of making beverages comprising the disclosed compositions.

To provide compositions and methods for use in the treatment of Gram-positive bacterial infections.SOLUTION: The compound of formula I, or an optical isomer thereof, an isotopic isomer thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof. (A, B:N, CH. n:0 to 3. R0:H, CH2PO (OH) 2, etc. R1: (CH2) m {(V) o (CH2) p} q W (V: CH2, CH=CH, CO, etc. W:H, halo, substituted / unsubstituted C1-6 alkyl, and the like. m:1-5. O, p, q:0-4). R2:H, halo, CN, etc. R3:Cl, F, Br, I, OH, etc. ) SELECTED DRAWING: None

The utility model provides a spherical tablet, and belongs to the field of pharmaceutical preparations. The spherical tablet comprises an upper hemisphere, a lower hemisphere and a middle belt, and the middle belt is located in the middle of the spherical tablet and is in a belt shape with the same thickness. The upper hemisphere and the lower hemisphere are located on the two end faces of the middle belt, and the two hemispheres are the same in size and shape. The diameter of the middle zone is larger than the diameter of the hemisphere, the diameter of the hemisphere of an upper stamping die and the diameter of the hemisphere of a lower stamping die of a tablet pressing die adopted when the spherical tablet is pressed ranges from 6.5 mm to 10 mm, and the ratio of the arc depth to the diameter of the hemisphere is (0.2-0.4): 1. The spherical tablet is small in size, easy to swallow, high in drug loading capacity and less in taking quantity; and the tablet has the advantages of good compressibility, good hardness, strong shock resistance and wear resistance, small tablet weight difference, facilitation of later coating and other operations, and good uniformity and reproducibility.

The application belongs to the field of medicinal chemistry, and provides a compound as an Akt kinase inhibitor, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition containing the compound, and use of the compound in preparation of a medicament for treating an Akt kinase related disease.

PPAB derived near-infrared super-small fluorescent silica nanoparticles and synthesis method and application thereof, the fluorescent silica nanoparticles prepared by the present application exhibit strong near-infrared fluorescence and good water solubility, have a strong fluorescence emission peak near 650 nm-700 nm wavelength, exhibit good fluorescence spectrum performance, and therefore the silicon quantum dots have relatively good cell tissue penetration. Due to the unique optical properties and relatively good cell tissue penetration, the in vivo fluorescence imaging can be effectively carried out. The fluorescent silica nanoparticles prepared by the present application have excellent singlet oxygen generation performance and peroxidase performance in addition to excellent near-infrared optical performance and good biocompatibility, can be used as a photodynamic / chemodynamic synergistic treatment reagent, and are used for antibacterial and antitumor applications, and have no toxic side effects on the organism itself.

Provided herein are compounds of formula (I), (I), a compound selected from any one of the compounds in Table 1, Table 2, Table 3, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R1, R2, R3, and R4 are as defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or a compound selected from any of the compounds in Table 1, Table 2, Table 3, or a pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of Formula (I) or a pharmaceutically acceptable salt or deuterated form thereof, for example, in the treatment of a 5-HT2A receptor associated disease or disorder.

To provide an agent useful for photoimmunotherapy.SOLUTION: A complex has one or more antibody molecules, a particle with an average particle size of 100 nm or less, and one or more photosensitive portions. In the complex, the particle with the average particle size of 100 nm or less is bound to the one or more antibody molecules. At least one of the antibody molecule and the particle is bound to the one or more photosensitive portions. The photosensitive portion is a portion that increases hydrophobicity upon irradiation with a light beam of 500-900 nm in wavelength or that includes a phthalocyanine skeleton.SELECTED DRAWING: None

The present invention aims to provide a novel compound having SF-1 antagonist activity and a polyfunctional molecule containing a moiety corresponding to the compound, particularly an SF-1 degrader. The present invention relates to a 3-phenylpropylamine derivative compound represented by the formula (1) and the like, and a polyfunctional molecule containing a moiety corresponding to the compound represented by the formula (1) and the like.

Disclosed herein are 3-[(1H-pyrazol-4-yl)oxy]pyrazin-2-amine compounds of Formula (I), or stereoisomers thereof, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same. Also disclosed are methods for modulating, e.g., inhibiting or treating, HPK1-related disorders or diseases, including cancer, by using the compounds disclosed herein. [Formula 1] JPEG2023543212000422.jpg63165

An object is to provide a pharmaceutical or the like that can prevent or treat an oxidative stress-induced disease. Provided is a preventive or therapeutic agent for an oxidative stress-induced disease, pharmaceutical composition, medical device, hygienic product, food, or beverage containing silicon small particles. When the silicon small particles are orally administered or placed on a skin or a mucous membrane, the oxidative stress-induced disease can be prevented or treated. The oxidative stress-induced disease is an inflammatory disease, depression, or the like, and an excellent preventive and therapeutic effect thereon is obtained.

To provide a 2,6-dioxo-3,6-dihydropyrimidine compound that has excellent bactericidal activity, has excellent safety, and can be industrially favorably synthesized, and an agricultural and horticultural fungicide, a nematicide, and an antifungal agent for use in medicine / animals that contain the compound as an active ingredient.SOLUTION: A compound represented by Formula (II) or a salt thereof is provided.SELECTED DRAWING: None

The present invention provides a formula for a traditional Chinese medicine-based feminine care solution and its preparation method. The care solution consists of, by weight, 10-15 parts rose hydrosol, 3-5 parts mint hydrosol, 30-45 parts traditional Chinese medicine extract, 3-5 parts dipterocarpus, 1-5 parts chelated platinum ion, and 6-12 parts bacteriostatic agent. The preparation method involves adding the rose hydrosol and mint hydrosol to the traditional Chinese medicine extract to obtain a concentrate. The concentrate is then diluted, and the dipterocarpus is added. The mixture is thoroughly stirred and filtered to obtain a filtrate. The chelated platinum ion and bacteriostatic agent are then added and stirred uniformly.

The present disclosure provides methods for treating, preventing, alleviating, inhibiting, or delaying the onset of Like's syndrome in a subject in need thereof, and methods for alleviating, inhibiting, alleviating, inhibiting, or delaying the onset of related signs and / or symptoms of Like's syndrome, the methods comprise administering to the subject various compounds, mixtures of compounds, or compositions, formulations, or medicaments derived therefrom. The disclosure further provides compositions, formulations, or medicaments and related uses for treating, preventing, alleviating, inhibiting, or delaying the onset of Like's syndrome in a subject and addressing signs and / or symptoms associated therewith.

The invention discloses an antioxidant mesoporous organic silicon self-assembled nano material as well as a preparation method and application thereof, and belongs to the technical field of nano materials and biomedicine. The method comprises the following steps: S1, preparing an ROS removal micromolecule precursor TK-NH2 through a mercaptan condensation reaction; s2, preparing antioxidant mesoporous organic silicon spheres (PMOs) by taking TK-NH2 as a raw material through a sol-gel method; and S3, preparing the antioxidant mesoporous organic silicon self-assembled nano material (PMOs (at) Cur (at) Ca) by taking the PMOs as a raw material through an anti-solvent method. The method is simple in steps, normal in temperature and pressure, low in cost and capable of achieving large-scale production; the prepared antioxidant mesoporous organosilicon self-assembled nano material can be applied to preparation of drugs for treating inflammations, especially inflammatory bone diseases, by removing ROS (reactive oxygen species), especially drugs for treating rheumatoid arthritis.

Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions containing them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins. [Formula 1] TIFF2022547716000696.tif17118

To provide compounds, compositions thereof, and methods of using the same.SOLUTION: The present invention provides compounds, compositions thereof, and methods of using the same. The present invention relates to compounds and methods useful for modulating the Sestrin-GATOR2 interaction thereby selectively modulating mTORC1 activity indirectly. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with mTORC1. Such diseases, disorders, or conditions include diabetes, epilepsy, neurodegeneration, immune response, suppressed skeletal muscle growth, and cellular proliferative disorders (e.g., cancer) such as those described herein.SELECTED DRAWING: None

Compositions and methods for inactivating coronaviruses are provided. [Solution] A method for inactivating coronavirus, comprising the steps of preparing an inactivating composition comprising one or more CSA compounds in a carrier, and administering the inactivating composition to a subject, wherein the inactivating composition inactivates coronavirus virions in the subject or that come into contact with the subject.

As used herein, the formula (I) [Formula 1] JPEG2026503411000111.jpg45165 or a compound selected from any of the compounds of Table 1, Table 2, Table 3, Table 4, or Table 5, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R 1 , R 2 , R 3 , and R 4 is defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4, or Table 5, or a pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I), or a pharmaceutically acceptable salt or deuterated form thereof, for example, in the treatment of a 5-HT2A receptor-associated disease or disorder.

A transient oil-in-simethicone emulsion for oral administration wherein 5 simethicone is present from 50% to 80% by weight of the emulsion. Also described is the process for the preparation of the transient oil-in-simethicone emulsion and capsule dosage form.

The invention discloses a novel amide compound with a substituted diphenyl ether structure as well as a preparation method and application of the novel amide compound. The compound comprises a structure as shown in a general formula (I) or a general formula (II), and is characterized in that a benzo five-membered aromatic heterocycle (including but not limited to benzofuran, benzothiophene, indole and the like) is connected with a substituted diphenyl ether group through an amido bond to form a unique molecular skeleton. Diversified substituent groups R1 such as halogen, alkyl and heterocyclic rings can be introduced into a benzene ring, substituent groups R2 such as alkyl and alkoxy (n is an integer from 0 to 2) are introduced into an intermediate connecting chain, and therefore diversity optimization of the molecular structure is achieved. A biological activity test shows that the compound has remarkable proliferation inhibition activity on SK-N-AS neuroblastoma cells, and shows potential treatment value on malignant tumors such as neuroblastoma. Through systematic molecular design, a substituted diphenyl ether structure compound with a novel structure is constructed, and a brand new chemical entity is provided for developing new anti-cancer drugs.